دورية أكاديمية
Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection.
| العنوان: | Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection. |
|---|---|
| المؤلفون: | Bachelard A; Assistance Publique-Hôpitaux de Paris.Nord, Service des Maladies Infectieuses et Tropicales, Hôpitaux Universitaires Paris Nord Val de Seine, site Bichat-Claude Bernard, Paris, France., Le Hingrat Q; Assistance Publique-Hôpitaux de Paris.Nord, Service de Virologie, Hôpitaux Universitaires Paris Nord Val de Seine, site Bichat-Claude Bernard, Paris, France.; Université Paris Cité, INSERM UMRS1137 IAME, Paris, France., Ferré VM; Assistance Publique-Hôpitaux de Paris.Nord, Service de Virologie, Hôpitaux Universitaires Paris Nord Val de Seine, site Bichat-Claude Bernard, Paris, France.; Université Paris Cité, INSERM UMRS1137 IAME, Paris, France., Lê M; Assistance Publique-Hôpitaux de Paris.Nord, Service de Pharmacologie, Hôpitaux Universitaires Paris Nord Val de Seine, site Bichat-Claude Bernard, Paris, France., Peytavin G; Université Paris Cité, INSERM UMRS1137 IAME, Paris, France.; Assistance Publique-Hôpitaux de Paris.Nord, Service de Pharmacologie, Hôpitaux Universitaires Paris Nord Val de Seine, site Bichat-Claude Bernard, Paris, France., Damond F; Assistance Publique-Hôpitaux de Paris.Nord, Service de Virologie, Hôpitaux Universitaires Paris Nord Val de Seine, site Bichat-Claude Bernard, Paris, France.; Université Paris Cité, INSERM UMRS1137 IAME, Paris, France., Charpentier C; Assistance Publique-Hôpitaux de Paris.Nord, Service de Virologie, Hôpitaux Universitaires Paris Nord Val de Seine, site Bichat-Claude Bernard, Paris, France.; Université Paris Cité, INSERM UMRS1137 IAME, Paris, France., Fremont Goudot G; Service des Maladies Infectieuses, CHI André Grégoire Montreuil, France., Goupil de Bouille J; Assistance Publique-Hôpitaux de Paris, Service des Maladies Infectieuses et Tropicales, Hôpitaux Universitaires Paris Seine Saint-Denis, site Avicennes, Bobigny, France., Lariven S; Assistance Publique-Hôpitaux de Paris.Nord, Service des Maladies Infectieuses et Tropicales, Hôpitaux Universitaires Paris Nord Val de Seine, site Bichat-Claude Bernard, Paris, France., Delobel P; Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.; INSERM UMR1291-CNRS UMR5051, Université Toulouse III, Toulouse, France., Yazdanpanah Y; Assistance Publique-Hôpitaux de Paris.Nord, Service des Maladies Infectieuses et Tropicales, Hôpitaux Universitaires Paris Nord Val de Seine, site Bichat-Claude Bernard, Paris, France.; Université Paris Cité, INSERM UMRS1137 IAME, Paris, France., Descamps D; Assistance Publique-Hôpitaux de Paris.Nord, Service de Virologie, Hôpitaux Universitaires Paris Nord Val de Seine, site Bichat-Claude Bernard, Paris, France.; Université Paris Cité, INSERM UMRS1137 IAME, Paris, France., Matheron S; Assistance Publique-Hôpitaux de Paris.Nord, Service des Maladies Infectieuses et Tropicales, Hôpitaux Universitaires Paris Nord Val de Seine, site Bichat-Claude Bernard, Paris, France.; Université Paris Cité, INSERM UMRS1137 IAME, Paris, France., Ghosn J; Assistance Publique-Hôpitaux de Paris.Nord, Service des Maladies Infectieuses et Tropicales, Hôpitaux Universitaires Paris Nord Val de Seine, site Bichat-Claude Bernard, Paris, France.; Université Paris Cité, INSERM UMRS1137 IAME, Paris, France. |
| مؤلفون مشاركون: | ANRS CO05 VIH-2 cohort study group |
| المصدر: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Apr 10; Vol. 78 (4), pp. 1005-1010. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Jan. 2011- : Oxford : Oxford University Press Original Publication: Chicago, IL : The University of Chicago Press, c1992- |
| مواضيع طبية MeSH: | Anti-HIV Agents*/therapeutic use , HIV Infections*/drug therapy , Antibodies, Monoclonal*, Humans ; Foscarnet/therapeutic use ; HIV-2 ; Salvage Therapy |
| مستخلص: | We evaluated Ibalizumab (IBA)-containing standardized optimized salvage regimen (with or without a 4-week foscarnet induction) in individuals harboring multidrug-resistant human immunodeficiency virus type 2 (HIV-2). Nine were included; 2 achieved virological suppression after foscarnet induction with a sustained suppression at Week 24 after IBA initiation, and an additional individual at Week 24 after Ibalizumab initiation. Competing Interests: Potential conflicts of interest. J. G. reports receiving support as an advisor for Gilead Sciences, MSD, Roche, Astra-Zeneca, Theratechnologies and ViiV. S. L. and G. F. G. report receiving support for attending medical conferences from Gilead. D. D. reports grants or contracts, honoraria as an advisor, and support for attending medical conferences from ViiV, Gilead and MSD. V.-M. F. reports payment or honoraria for speaking engagements from Astra-Zeneca and Moderna; travel support from Gilead, and receiving equipment, materials, drugs or other services from Copan. C. C. reports receiving honoraria as an advisor and support for attending medical conferences from MSD, Gilead, and ViiV. G. P. reports receiving grants or contracts from Gilead Sciences, ViiV Healthcare, Merck France, and Takeda; consulting fees from Gilead Sciences and ViiV Healthcare; payment for speaking engagements from Gilead Sciences and ViiV Healthcare; travel support from Gilead Sciences; and payment for Advisory of Data Safety Monitoring Board participation from Gilead Sciences and ViiV Healthcare. P. D. and S. M. report an unpaid role for French guidelines for antiretroviral therapy (HAS, ANRS, CNS). All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.) |
| معلومات مُعتمدة: | French National Agency for Research |
| فهرسة مساهمة: | Investigator: J Ghosn; S Matheron; V Appay; B Autran; A Besseghir; S Couffin-Cardiergues; C Birklé; F Brun-Vezinet; C Charpentier; G Chêne; R Cheynier; F Collin; F Damond; D Descamps; S Eholie; D Ekouvie; C Faguard; D Lebrasseur; J Longobardi; L Marchand; M Muller-Trutwin; A Ozanne; V Petrov-Sanchez; G Peytavin; C Roy; A Saez-Cirion; F Simon; L Wittkop; MC Meyohas; K Lacombe; D Salmon; A Rami; G Pialoux; S Matheron; J Ghosn; R Tubiana; P De Truchis; MA Khuong-Josses; O Derradji; D Troisvallet; J Timsit; AS Lascaux; V Jeantils; O Bouchaud; O Patey; P Caraux-Paz; C Goujard; L Gérard; E Mortier; E Froguel; Y Welker; V Daneluzzi; P Genet; A Leprêtre; D Zucman; G Force; A Coutellier-Simon; J Deleuze; L Weiss; V Garrait; HM Colin; L Blum; PJ Lelièvre; A Dulioust; V Perrone; C Billy; C Winter; I Aupérin; I Torre; JM Molina; P Brunet; S Lamy; A Devidas; A Chabrol; E Rouveix; S Kernbaum; C Duvivier; MA Bouldouyre; L Bodard; P Imbert; C Rapp; F Boué; A Uludag; F Chaix; O Son; O Bouchaud; JP Viard; X Duval; AG Belan; V Grégoire; G Beck-Wirth; F Raffi; C Drobacheff; C Chirouze; T Allègre; R Verdon; I Poizot-Martin; C Daniel; M Machado; AL Lecapitaine; PB Marchou; P Delobel; L Bernard; Y Debab; P Leclercq; J Julien; J Moreau; I Ravaux; C Arvieux; C Michaud; D Makhloufi; G Lemoal; P Arsac; T Prazuck; A Lafeuillade; B Martha; P Perré; F Ajana; P Morlat; E Brottier; M Dupon; D Neau; JL Pellegrin; I Raymond; N Montagne; T May; H Wille; Y Douadi; J Reynes; JL Schmit; C Rouger; JL Berger; Y Poinsignon; C Jacomet; L Piroth; E Rosenthal; D Garipuy; M Michaud; A Riché; FP du Clary; A Naqvi; J Gaillat; D Rey; F Abino; P Mercié; P Morlat; PM Roger; E Aïssi; JM Chennebault; D Liné; N Randrianasolo; C Merle; P Granet; L Caunègre; L Cotte; L Boileau; JB Euzen; P Perfezou; N Lefebvre; JP Talarmin; C Chirouze; S Pavel; B Ponceau; J Saison; A Sotto; D Laureillard; A Vandendriessche; I Darasteanu; C Birklé; S Couffin-Cardiergues; D Lebrasseur; L Marchand; M Mecheri; V Petrov-Sanchez; T Saidi; A Sangaré; A Besseghir; N Chaghil-Boissière; G Chêne; F Collin; V Conte; M Dembelé; C Faguard; Y Khalil; J Longobardi; A Ozanne; M Pallier; L Pinoges; C Roy; L Wittkop; S Chalal; L Oualit; L Becam; S Cirscota; C Lascoux; L Leger; M LeGoff; I Pellegrin; F Brun-Vezinet; C Charpentier; F Damond; D Descamps; L Youssef; R Cheynier; F Brun-Vézinet; B Autran; R Cheynier; G Pancino; A Hosmalin; V Vieillard; V Appay; F Brun-Vézinet; A Saez-Cirion Keywords: HIV-2; foscarnet; ibalizumab; multi-drug resistance; salvage therapy |
| المشرفين على المادة: | 364P9RVW4X (Foscarnet) LT369U66CE (ibalizumab) 0 (Anti-HIV Agents) 0 (Antibodies, Monoclonal) |
| تواريخ الأحداث: | Date Created: 20240417 Date Completed: 20240419 Latest Revision: 20240419 |
| رمز التحديث: | 20240419 |
| DOI: | 10.1093/cid/ciad695 |
| PMID: | 38630945 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1537-6591 |
|---|---|
| DOI: | 10.1093/cid/ciad695 |